Amgen(NASDAQ:AMGN) stock is trending and up about 12% as of this writing. The shares are rallying after the drugmaker’s CEO said he was encouraged by preliminary data on Amgen’s weight-loss drug. These comments also sparked a decline in shares ofNovo Nordisk(NYSE:NVO) stock. Novo ...
He also sees GLP-1 drugmakers following a similar trajectory to AI-linked stocks. "It's a little bit like thinking aboutNvidiawith AI. They just have a head start," Mazza said. "[Eli Lilly and Novo Nordisk] pivoted to focus on diabetes and weight ...
Barclays analyst Carter Gould said in a December note that it is "increasingly apparent" that the company will have to look externally for an obesity treatment, whether that's through an acquisition or partnership, to capture a slice of the weight loss drug market like it had hoped. Meanwhile...
When you think of a top weight loss drug, chances are that Ozempic is the name that first comes to mind. Although it is approved for diabetes (Wegovy is the equivalent version, which is approved for weight loss), many people have been using it for years to lose weight, and it...
Shares of Corbus, which is working on a similar weight-loss drug, crashed 62.3% to 19.51.Meanwhile, shares of companies working on GLP-1-based drugs jumped. Eli Lilly (LLY) stock rose 0.7% to 921.49. Shares of Viking Therapeutics (VKTX) and Structure Therapeutics (GPCR) advanced ...
Some analysts have said the weight-loss drug market could reach $150 billion a year in the next decade. "We know treatment of obesity is linked to better medical outcomes, even if bureaucrats haven't figured out how to account for these savings," Novo Nordisk...
weight-loss potential and management of diabetes and other health conditions. DehydraTECH may become a game changer in the multibillion-dollar GLP-1 drug market and could potentially lead to a collaboration with a dominant player in the space, such asNovo Nordisk(NYSE: NVO),Pfizer Inc.(NYSE:...
Novo Nordisk (NYSE:NVO) and Viatris Settle Patent Dispute for Weight-Loss Drugs Vince CondarcuriOct 08, 2024, 05:51 AM A+ A- Novo Nordisk (NVO) and Viatris (VTRS) have agreed to settle a dispute over patents for Novo’s weight-loss drugs, Ozempic and Wegovy, according to Reuters....
The weight loss drug market is growing in leaps and bounds -- and today the biggest winners areEli LillyandNovo Nordisk. These big pharma companies are bringing in billions thanks to their drugs that are helping those suffering from obesity shed pounds fast. But s...
But weight-loss drugs are a dynamic market, closely watched by Wall Street. Shares of Big Pharma stocksAstraZeneca(AZN) andRoche(RHHBY) have risen on news of their efforts in obesity treatment.Amgen(AMGN) stock has trended higher since May as Wall Street watches for more detail...